Study summary
A bedtime pill reduced breathing pauses by 44%
44.1% vs 17.6%reduction in breathing pauses, AD109 vs placebo
What was tested
AD109, a once-nightly pill combining aroxybutynin and atomoxetine to keep throat muscles active during sleep, against placebo for 26 weeks.
What they found
- Breathing pauses fell by 44.1% with AD109 and 17.6% with placebo.
- 22.3% of people on AD109 had their apnea fully controlled.
- A second phase 3 trial, in people who could not tolerate CPAP, was also positive.
- The FDA accepted the application in July 2026.
What it means
Would be the first pill for sleep apnea, and the first drug option that does not depend on weight loss.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.